Mark Birch
Angel investor in New York City
New York City, New York
Mark Birch, Angel investor in New York City is an active investor based in New York City, New York. This profile covers what Mark Birch backs, at which stage, and how founders can reach out in 2026.
- Investor type
- Angel
- Stages
- Seed
- Invests in
- SaaS & EnterpriseMarketing & AdTech
- Location
- New York City, New York
- Typical check
- $250K
- Past investments
- 2
Notable investments
ProfitablyOnepagerHow to reach Mark Birch
Angels and operators like Mark Birch reply to specific, personalized notes that show real traction, not mass blasts. Build a verified list, write a note that fits their thesis, and track replies, all on Round Funded.
Connect with Mark Birch
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise.
Frequently Asked Questions
What does Mark Birch invest in?
Mark Birch invests in SaaS & Enterprise and Marketing & AdTech, typically at Seed. Match your sector and stage, then reach out with a personalized pitch.
What stage does Mark Birch invest at?
Mark Birch typically invests at Seed. Lead with traction that fits the stage when you reach out.
What is Mark Birch's typical check size?
Mark Birch typically writes checks around $250K. Use it as a signal for whether your raise fits their stage.
How do I contact Mark Birch?
Unlock Mark Birch's verified email on Round Funded and send a personalized pitch. We surface only deliverable contacts so your outreach lands.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.